 EMERYVILLE, Calif., Oct. 18, 2021 PRNewswire -- Dynavax Technologies Corporation Nasdaq: DVAX, a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Valneva SE reported positive topline results from the Phase 3 pivotal trial of VLA2001, their inactivated COVID-19 vaccine candidate using Dynavaxs CpG 1018 adjuvant. 